Nov 15, 18 05:03 PM
heatwave kills more people than earthquakes
Nov 15, 18 05:02 PM
Mednews announcements of latest treatments, medicines and discoveries
Nov 14, 18 10:29 AM
cancer a fight we can win
29.9.2017 Super Malaria
Experts are issuing warnings over the rapid spread of 'super malaria' in South East Asia, but what exactly is it? And should we be worried?
Standard malaria can be prevented through the use of anti-malarial tablets, but the BBC reports that this dangerous new form of the parasite cannot be killed in a similar manner. This means that the life-threatening condition is beginning to spread through parts of Thailand, Laos and Vietnam, morphing into a disease that is potentially untreatable. Speaking to the BBC, professor Arjen Dondorp – who is head of malaria at the Mahidol-Oxford Tropical Medicine Research Unit in Bangkok – said:
"We think ['super malaria'] is a serious threat. It is alarming that this strain is spreading so quickly through the whole region and we fear it can spread further [and eventually] jump to Africa."
Malaria: The facts
Malaria is a disease caused by a parasite that is spread via blood-sucking mosquitoes. Symptoms include a high temperature, sweats and chills, headaches, vomiting and muscle pain. It is only present in certain countries – mainly tropical regions – but can be potentially fatal if left untreated (especially in children).
Normally an infected person would be treated with a combination of artemisinin and piperaquine, but certain malaria parasites are starting to become resistant to both drugs. Writing in The Lancet Infection Diseases, researchers declared that "the evolution and subsequent transnational spread of this single fit multidrug-resistant malaria parasite lineage is of international concern."
Although the UK is malaria-free, this does raise concern for those travelling to infected countries – particularly areas of Africa, where 92% of all cases occur.
Now, as the rate of treatment failure rises to 60% in Cambodia, some scientists say that time is running out to eliminate the disease. Prof Dondorp said:
"It's a race against the clock – we have to eliminate it before malaria becomes untreatable again and we see a lot of deaths. If I'm honest, I'm quite worried."
Also commenting on the above was Michael Chaw of the Wellcome Trust medical research charity, who hypothesised that the latest malaria strain could see the number of people dying from drug resistant infections every year (currently 700,000 globally) "increase to millions of people by 2050" if nothing is done.
If you are travelling abroad and are worried about malaria, here are some simple steps you can take to reduce risk.
Check whether you need to take prevention tablets
Use a strong insect repellent,
make sure you keep your arms and legs covered
keep all windows and doors closed
use a mosquito net when sleeping
It's important not to panic. If you are concerned about travelling to a country where there is a risk of malaria, consult your doctor or read the NHS's Fit For Travel advice.
Malaria killed about 440,000 people—mostly young children—last year, but a new drug candidate may help fight the disease.
Scientists are now ready to test the compound, which literally blows up malaria parasites in the blood stream, in people, says Spencer Knapp, a chemistry professor at Rutgers University.
Malaria is particularly lethal to children under five, who accounted for 70 percent of the roughly 440,000 deaths.
“That’s actually a very exciting development. The drugs that are out there are starting to encounter resistance, so this is a new drug candidate just now entering trials. We don’t know how effective it will be yet in humans.”
The compound, code-named SJ733, works in a new way, says Knapp, who first prepared the chemical in his lab. It binds to a malaria parasite protein that serves as a sodium (salt) pump. The pump is designed to get rid of sodium, but the compound blocks or interferes with the protein, and sodium ions build up. That allows water to rush in, blowing up the parasite inside human blood cells.
Malaria, a mosquito-borne disease, can make people very sick. Fever, chills, and flu-like illness are common symptoms, according to the US Centers for Disease Control and Prevention. More severe cases of malaria can lead to seizures, coma, severe anemia, acute respiratory distress, kidney failure, and other problems.
The United States was deemed malaria-free in 1949, according to the CDC. But last year, an estimated 214 million people worldwide contracted malaria, according to the World Health Organization. The scourge is particularly lethal to children under five, who accounted for 70 percent of the roughly 440,000 deaths.
Africa is essentially ground-zero for malaria. Last year, 88 percent of malaria cases and 90 percent of deaths linked to the disease were there.
The good new is malaria cases and deaths have dropped significantly in recent years. Between 2000 and 2015, new malaria cases fell 37 percent globally and 42 percent in Africa. Malaria death rates plunged by 60 percent globally and 66 percent in Africa.[Scientists prove they can edit mosquito genes]
Three key reasons are greater use of insecticide-treated mosquito nets, indoor spraying and artemisinin-based combination therapies. The latter medicines are very effective against P. falciparum, the deadliest and most common malaria parasite.
Large amounts of SJ733—4 kilograms or 8.8 pounds—were synthesized by contract for the clinical trials. The compound has been tested successfully in preclinical safety studies, with no side effects detected so far. “There are plenty of compounds that don’t make it through animal studies, but ours has made it through,” Knapp says.
The clinical trials could last as long as two years. During phase 1, SJ733—in the form of pills—will be given to healthy volunteers to assess the safety and pharmacokinetics of the compound. Pharmacokinetics are how drugs are absorbed, distributed, metabolized and eliminated by the body.
Then SJ733 would be tested in two phases of human malaria studies to find out if it works and if it’s safe.
“The thing about malaria is that really, really poor people have it, so the medicine has to be very inexpensive,” Knapp says. “We think that ours is going to be inexpensive.”
Rutgers is co-holder, with St. Jude Children’s Research Hospital in Memphis, Tennessee, and Medicines for Malaria Venture in Geneva, of a pending US patent.
Source: Rutgers UniversityHome Page - medical - Malaria